| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H35NO5S |
| Molecular Weight | 473.625 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)C1=CC=C(C=C1)N2[C@@H](COCC3=CC=C(S3)C(=O)OC(C)C)CCC2=O
InChI
InChIKey=MSIIJNOQQWRTFC-GGAORHGYSA-N
InChI=1S/C26H35NO5S/c1-4-5-6-7-23(28)19-8-10-20(11-9-19)27-21(12-15-25(27)29)16-31-17-22-13-14-24(33-22)26(30)32-18(2)3/h8-11,13-14,18,21,23,28H,4-7,12,15-17H2,1-3H3/t21-,23+/m1/s1
| Molecular Formula | C26H35NO5S |
| Molecular Weight | 473.625 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Simenepag isopropyl (AGN-210669) is an ophthalmic solution with potential intraocular pressure (IOP) lowering effects. Although the mechanism of action has not been disclosed, it is likely to be a sustained-release formulation of the EP agonist, AGN-210961. Simenepag isopropyl has been used in trials studying the treatment of ocular hypertension and open-angle glaucoma.
Originator
Approval Year
Sample Use Guides
Drug: Simenepag isopropyl (AGN-210669) ophthalmic solution, 0.1%
One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Drug: AGN-210669 ophthalmic solution, 0.075%
One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Drug: AGN-210669 ophthalmic solution, 0.05%
One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Route of Administration:
Topical
